Danish pharma company Novo Nordisk has partnered with India’s Emcure Pharmaceuticals to launch a new weight‑loss drug in the country. The medicine will be marketed under the brand name Poviztra.
Emcure will handle marketing and distribution in India, leveraging its network to reach more patients. The drug is a 2.4 mg semaglutide injection, similar to Novo Nordisk’s global weight‑loss brand Wegovy.
Poviztra is intended for adults with a BMI of 30 or higher, or a BMI of 27 and above with at least one weight‑related health condition, such as diabetes or high blood pressure. It is administered once a week using a pen device available in multiple doses, up to 2.4 mg. The drug also helps reduce the risk of serious heart problems in overweight adults with heart disease.
India’s weight‑loss drug market is growing fast. Eli Lilly’s Mounjaro, launched earlier this year, has already gained strong sales, showing rising demand for effective obesity treatments.
Satish Mehta, CEO of Emcure, expressed pride in introducing a widely recognized weight‑loss therapy to the Indian market, while Jay Thyagarajan, Novo Nordisk’s Asia‑Pacific VP, highlighted that the partnership aims to make obesity treatments more widely available across the country.
Obesity is a major health concern in India, affecting millions and contributing to over 230 related health problems, including heart disease, fatty liver, joint issues, and kidney disease. Experts say it is a long-term condition influenced by genetics, lifestyle, and environment.
Pricing and availability of Poviztra in India are yet to be announced.
Also Read: PhysicsWallah IPO opens at ₹103‑109, weak initial demand